Brevan Howard Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Brevan Howard Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$186K	Buy	+17,401	New	+$168K	﹤0.01%	1921

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brevan Howard Capital Management's ELTX Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 17,401 shares worth $186K. The stake represents ﹤0.01% of the portfolio and ranks #1921 among its holdings.

47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Brevan Howard Capital Management held 17,401 shares of Elicio Therapeutics worth $186K as of Q1 2026.
Elicio Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
Elicio Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1921 holding.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.